Human Von Hippel-Lindau disease tumor suppressor (VHL) ELISA Kit | AE11684HU

Human Von Hippel-Lindau disease tumor suppressor (VHL) ELISA Kit | AE11684HU | Gentaur UK, US & Europe Distribution

Species Reactivity: Human (Homo sapiens)

Abbreviation: VHL

Alternative Name: HRCA1; RCA1; VHL1; elongin binding protein

Application: ELISA

Range: 0.78-50 ng/mL

Sensitivity: 0.32 ng/mL

Intra-Assay: ≤4.5%

Inter-Assay: ≤7.5%

Recovery: 0, 97

Sample Type: Serum, Plasma, Other biological fluids

Detection Method: Sandwich

Analysis Method : Quantitive

Test Principale: This assay employs a two-site sandwich ELISA to quantitate VHL in samples. An antibody specific for VHL has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyVHL present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for VHL is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of VHL bound in the initial step. The color development is stopped and the intensity of the color is measured.

Product Overview: Von Hippel-Lindau (VHL) tumor suppressor protein is a component of an E3 ubiquitin ligase complex that selectively ubiquitinates the alpha subunit of the hypoxia-inducible factor (HIF) transcription factor for proteasome-mediated degradation. Inactivation of VHL causes VHL disease and sporadic kidney cancer.VHLL encodes a VHL homolog that lacks one of two key domains necessary for VHL function. This gene may contribute to the regulation of oxygen homeostasis and neovascularization during placenta development. This gene is intronless, and can also be interpreted as a retrotransposed pseudogene of the VHL locus located on chromosome 3. The same publication also indicates that this protein binds HIF alpha but fails to recruit the E3 ubiquitin ligase complex, and it therefore functions as a dominant-negative VHL protein and a protector of HIF alpha.

Stability: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. The loss rate was determined by accelerated thermal degradation test. Keep the kit at 37°C for 4 and 7 days, and compare O.D.values of the kit kept at 37°C with that of at recommended temperature. (referring from China Biological Products Standard, which was calculated by the Arrhenius equation. For ELISA kit, 4 days storage at 37°C can be considered as 6 months at 2 - 8°C, which means 7 days at 37°C equaling 12 months at 2 - 8°C) .